IMPLANET: insider trades · France · AMF

About IMPLANET

IMPLANET is a French medical technology company focused on orthopedic surgery implants, with a particularly strong specialization in spine surgery. Founded in 2007, the company is listed on Euronext Growth Paris under the ticker ALIMP and operates from Martillac, near Bordeaux, while also maintaining a U.S. subsidiary in Boston, established in 2013. At the core of IMPLANET’s business is the JAZZ® product range, a set of implants designed to improve the treatment of spinal disorders requiring spinal fusion. The company’s historical flagship is complemented by additional thoraco-lumbar screws, cages and cervical plates, notably through the acquisition of Orthopaedic & Spine Development (OSD) in May 2021. IMPLANET has also pursued strategic technology partnerships, most notably with Sanyou Medical, which led to the development of the Jazz Spinal System™, a hybrid posterior fixation system cleared by the U.S. FDA through the 510(k) process. From an industrial perspective, IMPLANET stands out for its collaborative model, bringing together surgeons, experienced engineers and product managers to design clinically grounded, user-friendly devices. The company states that its solutions are protected by several international patent families, and that JAZZ® has obtained key regulatory approvals in major markets, including CE marking in Europe, FDA clearance in the United States and ANVISA approval in Brazil. IMPLANET already has an international footprint, with commercial activity in 42 countries and a clear strategic emphasis on the United States, one of the most important markets for spine surgery worldwide. In 2025, the group continued to roll out new products and expanded its commercial presence, reporting full-year revenue of €12.5 million, up 33%, while narrowing its operating loss. This performance suggests an ongoing turnaround driven by product innovation, geographic expansion and a stronger commercial organization.